The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
Abstract
Purpose: We analyzed the benefits of a risk-adapted postremission strategy in adult lymphoblastic leukemia (ALL), and re-evaluated stem-cell transplantation (SCT) for high-risk ALL. Patients and Methods: A total of 922 adult patients entered onto the trial according to risk groups: standard-risk ALL (group 1), high-risk ALL (group 2), Philadelphia chromosome-positive ALL (group 3), and CNS-positive ALL (group 4). All received a standard four-drug/4-week induction course. Patients from group 1 who achieved a complete remission (CR) after one course of induction therapy were randomly assigned between intensive and less intensive postremission chemotherapy, whereas those who achieved CR after salvage therapy were then included in group 2. Patients in groups 2, 3, and 4 with an HLA-identical sibling were assigned to allogeneic SCT. In groups 3 and 4, autologous SCT was offered to all other patients, whereas in group 2 they were randomly assigned between chemotherapy and autologous SCT. Results: Overall, 771 patients achieved CR (84%). Median disease-free survival (DFS) was 17.5 months, with 3-year DFS at 37%. In group 1, the 3-year DFS rate was 41%, with no difference between arms of postremission randomization. In groups 2 and 4, the 3-year DFS rates were 38% and 44%, respectively. In group 2, autologous SCT and chemotherapy resulted in comparable median DFS. Patients with an HLA-matched sibling (groups 2 and 4) had improved DFS. Three-year DFS was 24% in group 3. Conclusion: Allogeneic SCT improved DFS in high-risk ALL in the first CR. Autologous SCT did not confer a significant benefit over chemotherapy for high-risk ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Larson, R., Dodge, R., Burns, C., Lee, E., Stone, R., Schulman, P., Duggan, D., Davey, F., Sobol, R., & Frankel, Sr. (1995) · Blood · doi:10.1182/blood.v85.8.2025.bloodjournal8582025 · Cited by 626
Dombret, H. (2002) · Blood · doi:10.1182/blood-2002-03-0704 · Cited by 378
Self-citationKlein, J., Rizzo, J., Zhang, M.-J., & Keiding, N. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703260 · Cited by 278
Marrow transplantation for patients with acute lymphoblastic leukemia in remission
Thomas, E. D., Sanders, J., Flournoy, N., Johnson, F. L., Buckner, C. D., Ra, C., Fefer, A., Goodell, B., Storb, R. F., & Weiden, P. (1979) · Blood · doi:10.1182/blood.v54.2.468.468 · Cited by 265
Mahmoud, H. H., Rivera, G. K., Hancock, M. L., Krance, R. A., Kun, L. E., Behm, F. G., Ribeiro, R. C., Sandlund, J. T., Crist, W. M., & Pui, C.-H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290504 · Cited by 199
Gaynor, J., Chapman, D., Little, C., McKenzie, S., Miller, W., Andreeff, M., Arlin, Z., Berman, E., Kempin, S., & Gee, T. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.1014 · Cited by 170
Cited by
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., Durrant, I. J., Luger, S. M., Marks, D. I., Franklin, I. M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Goldstone, A. H., Richards, S. M., Lazarus, H. M., Tallman, M. S., Buck, G., Fielding, A. K., Burnett, A. K., Chopra, R., Wiernik, P. H., Foroni, L., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116582 · Cited by 778
Moorman, A. V., Harrison, C. J., Buck, G. A. N., Richards, S. M., Secker-Walker, L. M., Martineau, M., Vance, G. H., Cherry, A. M., Higgins, R. R., Fielding, A. K., et al. (2007) · Blood · doi:10.1182/blood-2006-10-051912 · Cited by 753
Huguet, F., Leguay, T., Raffoux, E., Thomas, X., Beldjord, K., Delabesse, E., Chevallier, P., Buzyn, A., Delannoy, A., Chalandon, Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6916 · Cited by 567
Self-citationModern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia
Grabher, C., von Boehmer, H., & Look, A. T. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1880 · Cited by 425
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
Toft, N., Birgens, H., Abrahamsson, J., Griškevičius, L., Hallböök, H., Heyman, M., Klausen, T. W., Jónsson, Ó., Palk, K., Pruunsild, K., et al. (2018) · Leukemia · doi:10.1038/leu.2017.265 · Cited by 409
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073528 · Cited by 366
Self-citationde Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011908 · Cited by 344
Self-citationBrüggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O. G., Asnafi, V, Baruchel, A., Bassan, R., Benoit, Y., et al. (2010) · Leukemia · doi:10.1038/leu.2009.268 · Cited by 341
Self-citationL-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Egler, R. A., Ahuja, S. P., & Matloub, Y. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.184769 · Cited by 334
“[84-87] Prospective studies have shown that clinical outcome is improved in AYAs treated with pediatric or pediatric-inspired protocols [Table 5][88-93] when compared with historical controls of patients treated on adult protocols.[94,95] A feature common to the pediatric protocols was the higher cumulative dose of as…”
BackgroundDeAngelo, D. J., Stevenson, K. E., Dahlberg, S. E., Silverman, L. B., Couban, S., Supko, J. G., Amrein, P. C., Ballen, K. K., Seftel, M. D., Turner, A. R., et al. (2015) · Leukemia · doi:10.1038/leu.2014.229 · Cited by 330
Oriol, A., Vives, S., Hernandez-Rivas, J. M., Tormo, M., Heras, I., Rivas, C., Bethencourt, C., Moscardo, F., Bueno, J., Grande, C., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.014274 · Cited by 291
Adult acute lymphoblastic leukemia: Concepts and strategies
Faderl, S., O'Brien, S., Pui, C., Stock, W., Wetzler, M., Hoelzer, D., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.24862 · Cited by 289
Yakoub-Agha, I., Mesnil, F., Kuentz, M., Boiron, J. M., Ifrah, N., Milpied, N., Chehata, S., Esperou, H., Vernant, J.-P., Michallet, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0952 · Cited by 268
Self-citationTavernier, E., Boiron, J.-M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404824 · Cited by 256
Self-citationLazarus, H. M. (2006) · Blood · doi:10.1182/blood-2005-11-4666 · Cited by 253
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Frey, N. V., & Porter, D. L. (2016) · Hematology · doi:10.1182/asheducation-2016.1.567 · Cited by 222
Metadata
- Authors
- Thomas, X., Boiron, J.-M., Huguet, F., Dombret, H., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., Vernant, J.-P., Tournilhac, O., Buzyn, A., Reman, O., Charrin, C., Boucheix, C., Gabert, J., Lhéritier, V., & Fiere, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-10-15
- Volume
- 22
- Issue
- 20
- Pages
- 4075-4086
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108008366
- Cited by
- 550
- References
- 8
- FWCI
- 25.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.